NASH Pipeline: Racing To The Finish
As industry closes in on the first approved drug therapy for non-alcoholic steatohepatitis, our infographic details the dozens of companies testing numerous mechanisms for the multi-factorial disease.
You may also be interested in...
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.
The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.